Cholestasis, Intrahepatic
Recent clinical, regulatory, research and industry developments relating to this disease.
Maternal hepatic immunology during pregnancy.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagil… (2022)
Accelerated approval — Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (P… (2021)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Cholestasis, Intrahepatic1
- Fatty Liver1
- Hyperemesis Gravidarum1
- Pre-Eclampsia1
Leading journals1
- Frontiers in immunology1
Leading researchers5
- Fang H1
- Meng Y1
- Shi Y1
- Yang L1
- Zhang L1
Affiliations (unnormalised)1
- School of Life Sciences and Food Engineering1
Reference
Authoritative identity, definition & identifiers.
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.